ISDA

Deposition Date 2002-09-23

Release Date 2004-04-06

Last Version Date 2024-11-20

Entry Detail

PDB ID:

1MU8

Keywords:

HYDROLASE/HYDROLASE INHIBITOR

Title:

thrombin-hirugen_l-378,650

Biological Source:

Source Organism:

Hirudo medicinalis (Taxon ID: 6421)
Homo sapiens (Taxon ID: 9606)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.00 Å

R-Value Work:

0.23

R-Value Observed:

0.20

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:THROMBIN
Gene (Uniprot):F2
Chain IDs:A
Chain Length:36
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P00734 Pfam ID:PF09396, PF00089 EC:3.4.21.5

Protein Blast

Polymer Type:polypeptide(L)
Molecule:THROMBIN
Gene (Uniprot):F2
Chain IDs:B
Chain Length:259
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P00734 Pfam ID:PF09396, PF00089 EC:3.4.21.5

Protein Blast

Polymer Type:polypeptide(L)
Molecule:HIRUDIN IIB
Chain IDs:C
Chain Length:11
Number of Molecules:1
Biological Source:Hirudo medicinalis

UniProt ID:P28506

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
TYS	C	TYR	O-SULFO-L-TYROSINE

Ligand Molecules

CDB

Primary Citation

Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.

Burgey, C.S, Robinson, K.A, Lyle, T.A, Sanderson, P.E, Lewis, S.D, Lucas, B.J, Krueger, J.A, Singh, R, Miller-Stein, C, White, R.B, Wong, B, Lyle, E.A, Williams, P.D, Coburn, C.A, Dorsey, B.D, Barrow, J.C, Stranieri, M.T, Holahan, M.A, Sitko, G.R, Cook, J.J, McMasters, D.R, McDonough, C.M, Sanders, W.M, Wallace, A.A, Clayton, F.C, Bohn, D, Leonard, Y.M, Detwiler Jr, T.J, Lynch Jr, J.J, Yan, Y, Chen, Z, Kuo, L, Gardell, S.J, Shafer, J.A, Vacca, J.P.J.Show

J.Med.Chem. 46 461 473 (2003)

PMID: 12570369 DOI: 10.1021/jm020311f

Abstact

Recent efforts in the field of thrombin inhibitor research have focused on the identification of compounds with good oral bioavailability and pharmacokinetics. In this manuscript we describe a metabolism-based approach to the optimization of the 3-(2-phenethylamino)-6-methylpyrazinone acetamide template (e.g., 1) which resulted in the modification of each of the three principal components (i.e., P1, P2, P3) comprising this series. As a result of these studies, several potent thrombin inhibitors (e.g., 20, 24, 25) were identified which exhibit high levels of oral bioavailability and long plasma half-lives.

Legend

Protein

Chemical

Disease

Primary Citation of related structures